The legacy of Viagra and its influence on the pharmaceutical sector presents a challenging question regarding its continued appeal as an investment. Initially a phenomenal success, generating vast revenues, generic competition has significantly eroded financial returns. While established pharmaceutical firms continue patents on related therapies an

The outlook of companies tied to blockbuster drugs like Viagra presents a challenging investment picture. While the initial rise of copyright, fueled by Viagra's extraordinary popularity, generated substantial returns, the loss of exclusivity in key markets has introduced substantial volatility. Investors are now assessing the effect of generic com